Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin Dose-Ranging Study in Type 2 Diabetes
NCT01951235Phase 2Completed
- Sponsor
- Poxel SA
- Start
- Jan 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imeglimin in type 2 diabetes mellitus (T2DM), sponsored by Poxel SA. Started Jan 2013; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01951235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951235.